University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Arie Perry, MD

Arie Perry, MD

Professor of Pathology and Neurological Surgery; Director of Neuropathology; Director of Neuropathology Fellowship Training Program; Vice Chair of Pathology

Cancer Center Program Memberships

Neurologic Oncology

Research Summary

My clinical interests focus most heavily on surgical neuropathology, especially in terms of its application towards neuro-oncology. As a diagnostic neuropathologist with a focus on CNS tumors, I am primarily involved in translational research with the primary goal of developing new diagnostic and prognostic markers, which can be utilized in the clinical management of brain tumor patients. In order to achieve this goal, my lab has applied immunohistochemical, molecular cytogenetic, and genomic screening techniques primarily towards the study of gliomas, meningiomas, and primitive pediatric malignancies. I have been particularly interested in improved classification and grading schemes as well as the identification of molecular genetic markers associated with tumorigenesis, malignant progression, and/or biologic behavior. I collaborate with a number of clinical and scientific researchers both within and outside UCSF and it is our hope that the markers we identify will improve patient management and lead to the development of novel therapeutic approaches. I also maintain a private consultation service for difficult surgical neuropathology cases obtained from the U.S. and abroad, particularly brain tumors.

Education

The University of Texas at Austin, TX, B.S., 1986, Zoology
UT Southwestern Medical Center, Dallas, TX, M.D., 1990, M.D.
UT Southwestern Medical Center, Dallas, TX, Postdoctoral, 1994, Anatomic and Clinical Pathology Residency
Mayo Clinic, Rochester, MN, Postdoctoral, 1998, Surgical Pathology, Neuropathology, and Research Fellowships


Professional Experience

  • 1997-1998
    Mayo Clinic School of Medicine Instructor Pathology
  • 1998-2003
    Washington U. School of Medicine Assistant Professor Pathology
  • 2003-2008
    Washington U. School of Medicine Associate Professor Pathology
  • 2008-2010
    Washington U. School of Medicine Professor Pathology
  • 2009-2010
    Washington U. School of Medicine Professor Neurosurgery
  • 2010-present
    University of California, San Francisco Professor Pathology
  • 2010-present
    University of California, San Francisco Professor Neurosurgery

Honors & Awards

  • 1993
    First Place Resident Award (poster): Texas Society of Pathologists meeting
  • 1994
    First Place Resident Award (podium): Texas Society of Pathologists meeting
  • 1994
    Matthew T. Moore Award, International Congress of Neuropathology meeting
  • 1995
    Mary Tom Award, Canadian Association of Neuropathologists meeting
  • 1995-1997
    Fellowship Research Award, American Brain Tumor Association
  • 1999
    Distinguished Service Teaching Award, WUSM (Medical School Class of 2001)
  • 2002
    Lucien J. Rubenstein Award, American Association of Neuropathologists meeting
  • 2002
    Distinguished Service Teaching Award, WUSM (Medical School Class of 2004)
  • 2004
    Distinguished Service Teaching Award, WUSM (Medical School Class of 2006)
  • 2005
    Professor of the Year Award, WUSM (Medical School Class of 2007)
  • 2006-now
    America’s Top Doctors and America's Top Doctors for Cancer (Castle Connolly)
  • 2007
    Distinguished Service Teaching Award, WUSM (Medical School Class of 2009)
  • 2008
    Professor of the Year Award, WUSM (Medical School Class of 2010)
  • 2009-now
    Best Doctors in America, U.S. News and World Reports
  • 2009
    Distinguished Service Teaching Award, WUSM (Medical School Class of 2011)
  • 2013
    Nominated for MS1 Essential Core Teaching Award, UCSF (MS Class of 2016)

Selected Publications

  1. Pekmezci M, Cuevas-Ocampo AK, Perry A, Horvai AE. Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors. Mod Pathol. 2017 Aug 04.
    View on PubMed
  2. Chan E, Bollen AW, Sirohi D, Van Ziffle J, Grenert JP, Kline CN, Tihan T, Perry A, Gupta N, Solomon DA. Angiocentric glioma with MYB-QKI fusion located in the brainstem, rather than cerebral cortex. Acta Neuropathol. 2017 Aug 03.
    View on PubMed
  3. Chan AK, Han SJ, Choy W, Beleford D, Aghi MK, Berger MS, Shieh JT, Bollen AW, Perry A, Phillips JJ, Butowski N, Solomon DA. Familial melanoma-astrocytoma syndrome: synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A/B deletion and a significant family history. Clin Neuropathol. 2017 Jul 12.
    View on PubMed
  4. Sorge C, Li R, Singh S, Reddy AT, Solomon DA, Perry A, Friedman GK. Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature. Pediatr Blood Cancer. 2017 Jul 11.
    View on PubMed
  5. Ferris SP, Hofmann JW, Solomon DA, Perry A. Characterization of gliomas: from morphology to molecules. Virchows Arch. 2017 Jul 04.
    View on PubMed
  6. López G, Oberheim Bush NA, Berger MS, Perry A, Solomon DA. Diffuse non-midline glioma with H3F3A K27M mutation: a prognostic and treatment dilemma. Acta Neuropathol Commun. 2017 May 15; 5(1):38.
    View on PubMed
  7. Dahlin LB, Scherman P, Besjakov J, Lindberg E, Solomon DA, Horvai AE, Perry A. Intraneural glomus tumor of "uncertain malignant potential" and with BRAF mutation in the median nerve - an unusual case. Clin Neuropathol. 2017 Apr 25.
    View on PubMed
  8. Cuevas-Ocampo AK, Bollen AW, Goode B, Pajtler KW, Chavez L, Sharma T, Dai SC, McDermott M, Perry A, Korshunov A, Solomon DA. Genetic confirmation that ependymoma can arise as part of multiple endocrine neoplasia type 1 (MEN1) syndrome. Acta Neuropathol. 2017 Feb 25.
    View on PubMed
  9. Neill E, Luks T, Dayal M, Phillips JJ, Perry A, Jalbert LE, Cha S, Molinaro A, Chang SM, Nelson SJ. Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma. J Neurooncol. 2017 Mar; 132(1):171-179.
    View on PubMed
  10. Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor TT, Cairncross JG, Pfister SM, Rutkowski S, Weller M, Wick W, von Deimling A. Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathol. 2017 Jan; 133(1):1-3.
    View on PubMed
  11. Winkler EA, Birk H, Safaee M, Yue JK, Burke JF, Viner JA, Pekmezci M, Perry A, Aghi MK, Berger MS, McDermott MW. Erratum to: Surgical resection of fourth ventricular ependymomas: case series and technical nuances. J Neurooncol. 2016 Dec 30.
    View on PubMed
  12. Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor TT, Gregory Cairncross J, Pfister SM, Rutkowski S, Weller M, Wick W, von Deimling A. cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathol. 2016 Dec 20.
    View on PubMed
  13. Hirbe AC, Kaushal M, Sharma MK, Dahiya S, Pekmezci M, Perry A, Gutmann DH. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Cancer. 2016 Nov 22.
    View on PubMed
  14. Winkler EA, Birk H, Safaee M, Yue JK, Burke JF, Viner JA, Pekmezci M, Perry A, Aghi MK, Berger MS, McDermott MW. Surgical resection of fourth ventricular ependymomas: case series and technical nuances. J Neurooncol. 2016 Nov; 130(2):341-349.
    View on PubMed
  15. Ohba S, Mukherjee J, Johannessen TC, Mancini A, Chow TT, Wood M, Jones L, Mazor T, Marshall RE, Viswanath P, Walsh KM, Perry A, Bell RJ, Phillips JJ, Costello JF, Ronen SM, Pieper RO. Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process. Cancer Res. 2016 Nov 15; 76(22):6680-6689.
    View on PubMed
  16. Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, Perry A, Uppaluri R, Ferguson C, Schmidt RE, Dahiya S, Ansstas G, Mardis ER, Dunn GP. Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy. Cancer Discov. 2016 Nov; 6(11):1230-1236.
    View on PubMed
  17. Han SJ, Reis G, Kohanbash G, Shrivastav S, Magill ST, Molinaro AM, McDermott MW, Theodosopoulos PV, Aghi MK, Berger MS, Butowski NA, Barani I, Phillips JJ, Perry A, Okada H. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. J Neurooncol. 2016 Dec; 130(3):543-552.
    View on PubMed
  18. Phillips JJ, Gong H, Chen K, Joseph NM, van Ziffle J, Jin LW, Bastian BC, Bollen AW, Perry A, Nicolaides T, Solomon DA, Shieh JT. Activating NRF1-BRAF and ATG7-RAF1 fusions in anaplastic pleomorphic xanthoastrocytoma without BRAF p.V600E mutation. Acta Neuropathol. 2016 Sep 13.
    View on PubMed
  19. Olar A, Lapadat R, Davidson CJ, Stein TD, Dahiya S, Perry A, Gheorghe G. Central nervous system involvement by myeloid sarcoma: a report of 12 cases and review of the literature. Clin Neuropathol. 2016 Sep-Oct; 35(5):314-25.
    View on PubMed
  20. Gospodarev V, Câmara J, Chakravarthy V, Perry A, Wood M, Dietz R, Wang J, De Los Reyes K, Raghavan R. Treatment of IgG4-related pachymeningitis in a patient with steroid intolerance: The role of early use of rituximab. J Neuroimmunol. 2016 Oct 15; 299:62-65.
    View on PubMed

Go to UCSF Profiles, powered by CTSI